A comprehensive view of Regeneron Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Regeneron files Taiwanese patent application for medical device packaging for or a sterile syringe and related methods; invention may include a flexible tray having a cavity for containing the syringe: Application No. TW20200125581 20200729
Published: June 21, 2022 by Medical Patent News
Regeneron and Sanofi’s injectable anti-inflammatory drug Dupixent dupilumab cleared in US to treat children six months to five years old with atopic dermatitis or eczema; drug had previously been approved for children aged six years and older
Published: June 10, 2022 by SeeNews Pharmaceuticals
FDA accepts priority review of Regeneron and Sanofi’s sBLA for Dupixent Medical dupilumab injectable to treat adults with prurigo nodularis; if approved, Dupixent would be only drug to treat prurigo nodularis in US
Published: June 08, 2022 by M2 Pharma
Regeneron completes acquisition of clinical-stage biopharmaceutical company Checkmate Pharmaceuticals for US$10.50 per share of common stock, or approximately US$250M
Published: June 03, 2022 by Marketline - Deals
Regeneron buys exclusive worldwide rights to Libtayo injectable cancer drug from Sanofi for US$900M; Regeneron’s 2021 sales of Libtayo up 13% from 2020 to US$306M, with Sanofi sales of Libtayo up 91% last year to US$129M
Published: June 03, 2022 by FiercePharma

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count